Aptinyx (APTX) Gets a Buy Rating from Cowen & Co.

Cowen & Co. analyst Ritu Baral maintained a Buy rating on Aptinyx (APTX) yesterday. The company’s shares closed last Tuesday at $4.30.

According to TipRanks.com, Baral is a 5-star analyst with an average return of 12.8% and a 47.9% success rate. Baral covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Milestone Pharmaceuticals, and ACADIA Pharmaceuticals.

Currently, the analyst consensus on Aptinyx is a Strong Buy with an average price target of $10.00.

See today’s analyst top recommended stocks >>

Based on Aptinyx’s latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $490K and GAAP net loss of $12.52 million. In comparison, last year the company earned revenue of $925K and had a GAAP net loss of $12.13 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Aptinyx Inc. is a clinical stage biopharmaceutical company. It engages in the discovery, development, and and commercialization of transformative therapies for disorders of the brain and nervous system. Its product includes NYX-2925, NYX-783, NYX-458, and the AGN-241751 program. The company was founded by Norbert G. Riedel and Joseph R. Moskal in June 2015 and is headquartered in Evanston, IL.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts